Why Melexis (ENXTBR:MELE) Is Getting Attention Today
Q2 2026 results and fresh outlook put Melexis in focus
Melexis (ENXTBR:MELE) drew fresh attention after reporting Q2 2026 results that showed higher sales but lower net income compared with a year earlier, alongside new guidance for Q3 and the second half of 2026.
The company also affirmed an interim dividend of €1.30 per share, with shares due to trade ex coupon on 13 October 2026 and the record date set for 14 October 2026. Investors now have updated figures for both earnings and shareholder payouts as they assess the stock.
See our latest analysis for Melexis.
At a share price of €72.25, Melexis has a year to date share price return of 22.98%, while the 1 year total shareholder return of 9.79% contrasts with weaker 3 and 5 year total shareholder returns. This suggests that recent momentum has improved compared with the longer track record.
If Melexis has you looking more closely at semiconductor and automation trends, it might also be a good time to scan the market for other robotics and automation opportunities using the 37 robotics and automation stocks
Melexis combines a focused semiconductor business with a share price that has run ahead over 2026, while longer term returns look softer. Does that recent rebound still leave enough value on offer today?
Most Popular Narrative: 3.9% Undervalued
The most followed Melexis narrative points to a fair value of €75.15 compared with the latest close at €72.25, and builds that gap around specific growth and margin expectations.
Rising electrification in vehicles, including the shift to 48 volt architectures and advanced EV thermal management, supports sustained demand for motor drivers and current sensors. This may lift top line growth and support operating leverage as volumes scale.
Want to see what sits behind that valuation gap? The narrative leans on steady revenue expansion, higher profit margins and a richer earnings multiple to back its fair value call.
Result: Fair Value of €75.15 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Melexis narrative still faces clear risks if end market recovery stays muted, or if high inventories trigger pricing pressure and weaker margins.
Find out about the key risks to this Melexis narrative.
Next Steps
The mix of steady Melexis updates and shifting expectations can feel balanced between risk and reward, so act while the details are fresh and shape your own view by checking the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Melexis?
If Melexis has sharpened your focus, do not stop there. Broaden your watchlist with screens that can surface fresh opportunities across different styles and risk profiles.
- Hunt for quality at a discount by scanning the market using the 263 high quality undervalued stocks
- Strengthen your income stream by checking stocks that feature the 438 dividend fortresses
- Reduce potential downside by focusing on companies highlighted in the 295 resilient stocks with low risk scores
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com